• SENSEX
    NIFTY 50
Healthcare

Biosimilar drug Pegfilgrastim a large opportunity, says Biocon

Updated : June 05, 2018 11:26 PM IST

Fulphila is the first FDA-approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon's joint portfolio approved in the US.
Biocon is expected to launch the drug in FY19.
Biosimilar drug Pegfilgrastim a large opportunity, says Biocon

You May Also Like

Live TV
Advertisement